Trial Profile
A Phase II Study of Apatinib for Patients With Heavily Pretreated, Metastatic Esophageal Cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 13 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 Sep 2015 New trial record